U.S. markets closed

Collegium Pharmaceutical, Inc. (COLL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.80-0.40 (-2.08%)
At close: 04:00PM EDT
18.80 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close19.20
Bid7.56 x 800
Ask21.12 x 800
Day's Range18.77 - 19.44
52 Week Range14.04 - 22.89
Avg. Volume291,885
Market Cap641.573M
Beta (5Y Monthly)0.88
PE Ratio (TTM)16.94
EPS (TTM)1.11
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
103% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for COLL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Collegium Pharmaceutical, Inc.
    COLL: What does Argus have to say about COLL?COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of SELL; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Benzinga

    Analyst Sees This 'Specialty Pharma' Stock Stuck Until Prescription Trends Improve

    Last week, Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright has downgraded the stock to Neutral with no price target vs. prior Buy with a $29 target. "We applaud the recent financial results but have been disappointed by Xtampza and Belbuca Rx trends, which are below our projections, down slightly Y/Y, and trajectories currently flat at best," the analyst writes. The analyst believes that

  • Zacks

    Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates

    Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Collegium Reports Second Quarter 2022 Financial Results

    – Generated Record Net Revenue of $123.5 Million – – BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million – – Raises Full Year Adjusted EBITDA Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today reported its financial results for the quarter ended June 30, 2022 and provided a c